Background {#Sec1}
==========

Ductal carcinoma in situ (DCIS) is not an invasive malignant tumor; hence, it does not have the ability to metastasize. Therefore, the necessity of surgical treatment and sentinel lymph node biopsy for DCIS has been studied \[[@CR1]--[@CR4]\]. However, DCIS is diagnosed by histological examinations such as core needle biopsy (CNB) or vacuum-assisted biopsy (VAB), and invasion is often found in the postoperative pathological examination. A meta-analysis reported 25.9% (18.6--37.2%) of invasive ductal carcinomas (IDCs) are preoperatively diagnosed as DCIS by CNB \[[@CR5]\]. Although risk factors have been examined, no such factors exist that can be identified easily using blood tests.

Cancer affects the general body condition as it progresses. In particular, changes in the blood composition are often observed starting from an early stage. Tumor markers are often correlated with progression and they have been reported to change following recurrence before other symptoms can be detected using different tests \[[@CR6]--[@CR8]\]. Carcinoembryonic antigen (CEA) and cancer antigen 15--3 (CA15--3) are commonly used as tumor markers for breast cancer. The white blood cell population and blood chemistry can also change. Lactate dehydrogenase (LDH) is one of the most important metabolic enzymes involved in glycolysis \[[@CR9]\]. An increase in serum LDH is observed with tissue destruction caused by cancerous growth \[[@CR10]\], and serum LDH values ​​have been reported to be consistent with clinical TNM staging \[[@CR10], [@CR11]\]. Furthermore, the peripheral blood platelet--lymphocyte ratio (PLR) has been reported to be useful for predicting prognosis \[[@CR12]--[@CR14]\], and results from a meta-analysis suggested a correlation between the PLR and progression in breast cancer \[[@CR12]\].

Therefore, we hypothesized that there may be a difference in blood test results if invasion occurs in patients diagnosed with DCIS by preoperative biopsy. In this study, we identified predictors of invasion from preoperative blood tests in patients diagnosed with DCIS by preoperative biopsy.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

In this study, 100 and 18 patients who were diagnosed with DCIS by preoperative biopsy from August 2007 to January 2018 at the Osaka City University Hospital were included. Two breast pathologists jointly performed the pathological diagnosis and examination. The grade of DCIS was based on the World Health Organization classification \[[@CR15]\]. The presence of comedonecrosis and intraductal calcification was examined and lymphoid infiltrate was evaluated with reference to previous reports \[[@CR16], [@CR17]\]. Patients with multiple breast cancers were excluded, as were patients with a history of cancer regardless of breast cancer. Biopsies were performed by 16-gauge CNB or VAB with ultrasonography at the discretion of the attending physician. All patients underwent mastectomy or breast-conserving surgery. In both preoperative biopsy and postoperative pathological examination, invasion was examined by Hematoxylin-Eosin staining and immunohistochemical staining. Furthermore, the expression of the estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki67 was evaluated by immunohistochemical staining in the biopsy tissue. All patients underwent ultrasonography and computed tomography, and 90 patients (76.3%) underwent magnetic resonance imaging. Based on these results, tumor size was measured. None of the patients in this study had a suspected invasive carcinoma detected by imaging. Cases that were suspected of having lymph node metastases in the image were diagnosed as IDC even if they were diagnosed with DCIS by biopsy, and were excluded from this study.

Blood sample analysis {#Sec4}
---------------------

Peripheral blood was obtained before the biopsy. This study evaluated absolute platelet count, absolute lymphocyte count, LDH, CEA, and CA15--3. Patients in whom any of these variables was not measured were excluded from the study. The number of blood cells was determined using a hemocytometer. Percentages of different cell types were determined using a Coulter LH 750 Hematology Analyzer (Beckman Coulter, Brea, CA, USA). The PLR was calculated from the preoperative blood sample by dividing the absolute platelet count by the absolute lymphocyte count. Based on previous studies, a PLR value of 160.0 was used as the cutoff value to discriminate between a high PLR (≥160.0) and a low PLR (\< 160.0) \[[@CR18]\]. For LDH, CEA, and CA15--3, each upper limit of normal range (ULN) was set as a cut-off value (LDH: 120--242 IU/L, CEA: ≤5.0 ng/mL, CA15--3: ≤25.0 U/mL).

Statistical analysis {#Sec5}
--------------------

All statistical analysis was performed with the JMP software package (SAS, Tokyo, Japan). The relationship between each factor was examined using Pearson's chi-square test. The odds ratio (OR) and 95% confidence interval (CI) were calculated by logistic analysis. Multivariable analysis was performed using the multivariable logistic regression model. Significance was defined as a *p* value of less than 0.05.

Results {#Sec6}
=======

Clinicopathological features {#Sec7}
----------------------------

The clinicopathological features of 118 patients who were diagnosed with DCIS by preoperative biopsy and met the conditions of this study are shown in Table [1](#Tab1){ref-type="table"}. The median age was 51 (range, 30--78) years, and the median tumor diameter was 17.7 mm (range, 3.0--50.0 mm). A breast lump was the most common cause of consultation in 63 patients (53.4%). As for other symptoms for consultation, 13 patients (11.0%) had nipple discharge, one patient (0.8%) had skin tangles, and one patient (0.8%) had discomfort. Six patients with breast lumps and three patients (2.5%) with nipple discharge had pain. Of all patients, 76 (64.4%) were detected as having subjective symptoms, while 42 (35.6%) were asymptomatic. Forty patients (33.9%) were found by breast cancer screening, and two patients (1.7%) were found by CT examination for other diseases. At consultation, a tumor was palpable in 85 patients (72.0%). VAB was selected for 51 patients (43.2%), but 67 patients (56.8%), which is more than half, were diagnosed preoperatively by 16-Gauge CNB. Ninety-six patients (81.4%) had ER-positive tumors, and 81 patients (68.6%) had PgR-positive tumors. Seventeen patients (14.4%) had a score of 3+ for HER2. Ki67 expression was detected in \> 14% in 20 patients (16.9%). Twenty preoperative biopsy specimens (16.9%) were pathologically high-grade. The eight patients diagnosed with low grade by biopsy had the diagnosis changed to intermediate grade by postoperative pathological examination, and two patients diagnosed with intermediate grade by biopsy had the diagnosis changed to low grade by postoperative pathological examination. However, in no patient, diagnosis was changed from low or intermediate to high grade or from high to not-high grade by postoperative pathological examination. Comedonecrosis was found in 64 patients (54.2%), and intraductal calcification was found in 19 cases (16.1%). As for lymphoid infiltrate, 35 patients (29.7%) were evaluated as moderate or severe. Forty-eight patients (40.7%) were found to have invasion by postoperative pathological examination. Table 1Clinicopathological features of 118 cases diagnosed with DCIS by preoperative biopsyParametersNumber of patients (*n* = 118) (%)Age at operation (years old)51 (30--78)Symptoms Asymptomatic / Symptomatic42 (35.6%) / 76 (64.4%)Palpability Impalpabe / Palpable33 (28.0%) / 85 (72.0%)Tumor size (mm)17.7 (3.0--50.0)Biopsy device Core needle biopsy / Vacuum-assisted biopsy67 (56.8%) / 51 (43.2%)Estrogen receptor Negative / Positive22 (18.6%) / 96 (81.4%)Progesterone receptor Negative / Positive37 (31.4%) / 81 (68.6%)HER2  ≤ 2 / 3101 (85.6%) / 17 (14.4%)Ki67  ≤ 14% / \> 14%98 (83.1%) / 20 (16.9%)Grade of DCIS Low, intermediate / High98 (83.1%) / 20 (16.9%)Comedonecrosis Absence / Presence54 (45.8%) / 64 (54.2%)Intraductal calcification Absence / Presence99 (83.9%) / 19 (16.1%)Lymphoid infiltrate Negative, mild / moderate, severe83 (70.3%) / 35 (29.7%)Postoperative pathology DCIS only / Invasive ductal carcinoma70 (59.3%) / 48 (40.7%)Platelets--lymphocyte ratiomedian 138.9 (range, 55.0--292.0) Low / High70 (59.3%) / 48 (40.7%)LDHmedian 170 (range, 121--452)  ≤ ULN / \>ULN105 (89.0%) / 13 (11.0%)CEAmedian 1.6 (range, \< 0.5--12.4)  ≤ ULN / \>ULN111 (94.1%) / 7 (5.9%)CA15--3median 6.6 (range, \< 0.5--40.8)  ≤ ULN / \>ULN115 (97.5%) / 3 (2.5%)*DCIS* Ductal carcinoma in situ, *HER2* Human epidermal growth factor receptor 2, *LDH* Lactate dehydrogenease, *CEA* Carcinoembryonic antigen, *ULN* Upper limit of normal

The median LDH level was 170 IU/L (range, 121--452 IU/L), and it was higher than the ULN in 13 patients (11.0%). The median CEA level was 1.6 ng/mL (range, \< 0.5--12.4 ng/mL), and it was higher than the ULN in 7 patients (5.9%). In addition, the median CA15--3 level was 6.6 U/mL (range, \< 0.5--40.8 U/mL), and in 3 patients (2.5%) it was higher than the ULN. The median PLR was 138.9 (range, 55.0--292.0), and 48 patients (40.7%) who had a PLR \> 160 were assigned to the high PLR group.

Correlations between clinicopathological features and postoperative pathology {#Sec8}
-----------------------------------------------------------------------------

The correlations between clinicopathological features and postoperative pathology are listed in Table [2](#Tab2){ref-type="table"}. DCIS detected by symptom was significantly more invasive than asymptomatic DCIS (*p* = 0.047). In cases in which the tumor was palpable before surgery, the postoperative pathology tended to be IDC (*p* = 0.065). In cases in which the tumor diameter was larger than 20 mm, the probability of the postoperative pathology being IDC was significantly higher (*p* = 0.024). Cases biopsied by VAB were significantly more likely to be diagnosed as DCIS by postoperative pathology than those biopsied by CNB (*p* = 0.003). Although no significant difference was observed based on immunohistochemical staining, invasion was found more frequently after surgery in pathologically high-grade cases than in pathologically not-high-grade cases (*p* = 0.015). Patients with comedonecrosis and those with intraductal calcification tended to have more invasive disease by postoperative pathology than patients without those conditions (*p* = 0.061, *p* = 0.098, respectively). Invasion rate was significantly higher in patients evaluated as moderate or severe for lymphoid infiltrate than in those evaluated as negative or mild (*p* = 0.018) **(**Fig. [1](#Fig1){ref-type="fig"}**)**. Table 2Correlation between postoperative pathology and clinicopathological featuresParametersPostoperative pathology*p* valueDCIS only\
(*n* = 70)Invasive ductal carcinoma\
(*n* = 48)Age at operation (years old)  ≤ 6050 (71.4%)33 (68.8%)  \> 6020 (28.6%)15 (31.3%)0.754Symptoms Asymptomatic30 (42.9%)12 (25.0%) Symptomatic40 (57.1%)36 (75.0%)0.044Palpability Impalpabe24 (34.3%)9 (18.8%) Palpable46 (65.7%)39 (81.3%)0.065Tumor size (mm)  ≤ 20.048 (68.6%)23 (47.9%)  \> 20.022 (31.4%)25 (52.1%)0.024Biopsy device Core needle biopsy32 (45.7%)35 (72.9%) Vacuum-assisted biopsy38 (54.3%)13 (27.1%)0.003Estrogen receptor Negative9 (12.9%)13 (27.1%) Positive61 (87.1%)35 (72.9%)0.051Progesterone receptor Negative18 (25.7%)19 (39.6%) Positive52 (74.3%)29 (60.4%)0.111HER2  ≤ 263 (90.0%)38 (79.2%) 37 (10.0%)10 (20.8%)0.100Ki67  ≤ 14%60 (85.7%)38 (79.2%)  \> 14%10 (14.3%)10 (20.8%)0.352Grade of DCIS Low, intermediate63 (90.0%)35 (72.9%) High7 (10.0%)13 (27.1%)0.015Comedonecrosis Absence37 (52.9%)17 (35.4%)Presence33 (47.1%)31 (64.6%)0.061Intraductal calcification Absence62 (88.6%)37 (77.1%) Presence8 (11.4%)11 (22.9%)0.098Lymphoid infiltrate Negative, mild56 (80.0%)27 (56.3%) Moderate, severe14 (20.0%)21 (43.8%)0.006Platelets--lymphocyte ratio Low50 (71.4%)24 (50.0%) High20 (28.6%)24 (50.0%)0.018LDH  ≤ ULN63 (90.0%)42 (87.5%)  \> ULN7 (10.0%)6 (12.5%)0.670CEA  ≤ ULN66 (94.3%)45 (93.8%)  \> ULN4 (5.7%)4 (5.7%)0.904CA15--3  ≤ ULN69 (98.6%)46 (95.8%)  \> ULN1 (1.4%)2 (4.2%)0.353*DCIS* Ductal carcinoma in situ, *HER2* Human epidermal growth factor receptor 2, *LDH* Lactate dehydrogenease, *ULN* Upper limit of normal, *CEA* Carcinoembryonic antigenFig. 1Forrest plot. Forest plot showed odd ratios for the univariate association of the clinicopathological features on postoperative pathology changes to invasive ductal carcinoma. In univariate analysis of factors predictive of invasion in postoperative pathology, a high PLR (*p* = 0.018, OR = 2.500) was a factor, as were larger tumor size (*p* = 0.024, OR = 2.372), non-Low Grade of DCIS (*p* = 0.015, OR = 3.343) and biopsy method (VAB vs. CNB, *p* = 0.003, OR = 0.313)

Examination of preoperative blood sampling results showed no significant difference in LDH level or tumor markers based on pre- and postoperative concordance. However, the high PLR group was significantly more likely to show invasion in postoperative pathology than the low PLR group (*p* = 0.018). The correlations between the PLR and other clinical factors were examined, but there was no clear correlation **(**Table [3](#Tab3){ref-type="table"}**)**. In the univariate analysis of factors predictive of invasion in postoperative pathology, a high PLR (*p* = 0.018, OR = 2.500) was a factor, as were larger tumor size (*p* = 0.024, OR = 2.372), high grade of DCIS (*p* = 0.015, OR = 3.343), moderate or severe for lymphoid infiltrate (*p* = 0.006, OR = 3.111), and biopsy method (VAB vs. CNB, *p* = 0.003, OR = 0.313) **(**Fig. [1](#Fig1){ref-type="fig"}**)**. Moreover, in multivariate analysis of factors predictive of invasion in postoperative pathology, a high PLR (*p* = 0.006, OR = 3.526) and biopsy method (VAB vs. CNB, *p* = 0.001, OR = 0.201) were independent factors **(**Table [4](#Tab4){ref-type="table"}**)**. Table 3Correlation between platelets--lymphocyte ratio and clinicopathological featuresParametersPlatelets--lymphocyte ratio*p* valueLow\
(*n* = 74)High\
(*n* = 44)Age at operation (years old)  ≤ 6051 (68.9%)32 (72.7%)  \> 6023 (31.1%)12 (27.3%)0.661Symptoms Asymptomatic29 (39.2%)13 (29.5%) Symptomatic45 (60.8%)31 (70.5%)0.290Palpability Impalpabe22 (29.7%)11 (25.0%) Palpable52 (70.3%)33 (75.0%)0.580Tumor size (mm)  ≤ 20.045 (60.8%)26 (59.1%)  \> 20.029 (39.2%)18 (40.9%)0.854Biopsy device Core needle biopsy42 (56.8%)25 (56.8%) Vacuum-assisted biopsy32 (43.2%)19 (43.2%)0.995Estrogen receptor Negative15 (20.3%)7 (15.9%) Positive59 (79.7%)37 (84.1%)0.556Progesterone receptor Negative25 (33.8%)12 (27.3%) Positive49 (66.2%)32 (72.7%)0.461HER2  ≤ 263 (82.4%)40 (90.9%) 313 (17.6%)4 (9.1%)0.205Ki67  ≤ 14%62 (83.8%)36 (81.8%)  \> 14%12 (16.2%)8 (18.2%)0.783Grade of DCIS Low, intermediate60 (81.1%)38 (86.4%) High14 (18.9%)6 (13.6%)0.460Comedonecrosis Absence36 (48.6%)18 (40.9%) Presence38 (51.4%)26 (59.1%)0.666Intraductal calcification Absence63 (85.1%)36 (81.8%) Presence11 (14.9%)8 (18.2%)0.635Lymphoid infiltrate Negative, mild49 (66.2%)34 (77.3%) Moderate, severe25 (33.8%)10 (22.7%)0.204LDH  ≤ ULN67 (90.5%)38 (86.4%)  \> ULN7 (9.5%)6 (13.6%)0.484CEA  ≤ ULN70 (94.6%)41 (93.2%)  \> ULN4 (5.4%)3 (6.8%)0.753CA15--3  ≤ ULN71 (95.9%)44 (100.0%)  \> ULN3 (4.1%)0 (0.0%)0.176Postoperative pathology DCIS only50 (67.6%)20 (45.5%) Invasive ductal carcinoma24 (32.4%)24 (54.5%)0.018*DCIS* Ductal carcinoma in situ, *HER2* Human epidermal growth factor receptor 2, *LDH* Lactate dehydrogenease, *ULN* Upper limit of normal. *CEA* Carcinoembryonic antigenTable 4Univariate and multivariate analysis with upstaging preoperatively DCIS to invasive cancerUnivarite analysisMultivarite analysisParametersOdd ratio95% CI*p* valueOdd ratio95% CI*p* valueAge at operation (years old)  ≤ 60 vs \> 601.1360.510--2.5310.754Symptoms Asymptomatic vs Symptomatic2.2501.004--5.0420.0472.2260.638--8.4630.217Palpability Impalpabe vs Palpable2.2610.941--5.4340.0650.8650.201--3.5680.842Tumor size (mm)  ≤ 20.0 vs \> 20.02.3721.111--5.0630.0242.6470.908--8.2610.075Biopsy device CNB vs VAB0.3130.142--0.6900.0030.2010.068--0.5340.001Estrogen receptor Negative vs Positive0.3970.154--1.0230.0511.0080.227--4.6330.991Progesterone receptor Negative vs Positive0.5280.240--1.1630.111HER2  ≤ 2 vs 32.3680.832--6.7440.1001.7390.361--8.4170.484Ki67  ≤ 14% vs \> 14%1.5790.601--4.1490.352Grade of DCIS Low, intermediate vs High3.3431.221--9.1550.0152.2340.526--9.9610.274Comedonecrosis Absence vs Presence2.0450.961--4.3500.0610.8170.303--2.1330.682Intraductal calcification Absence vs Presence2.3040.850--6.2480.0982.5250.748--9.0190.136Lymphoid infiltrate Negative, mild / moderate, severe3.1111.373--7.0460.0062.2960.752--7.2150.144Platelets--lymphocyte ratio Low vs High2.5001.160--5.3860.0183.5261.423--9.2580.006LDH  ≤ ULN vs \> ULN1.2860.404--4.0940.670CEA  ≤ ULN vs \> ULN1.1000.235--5.1520.904CA15--3  ≤ ULN vs \> ULN3.0000.264--34.0520.353*DCIS* Ductal carcinoma in situ, *CNB* Core needle biopsy. *VAB* Vacuum-assisted biopsy. *HER2* Human epidermal growth factor receptor 2, *LDH* Lactate dehydrogenease, *ULN* Upper limit of normal, *CEA* Carcinoembryonic antigen, *CI* Confidence intervals

Discussion {#Sec9}
==========

IDC may be misdiagnosed as DCIS by preoperative biopsy. As mentioned above, 25.9% (18.6--37.2%) of cases preoperatively diagnosed as DCIS have been reported to be IDC according to a meta-analysis \[[@CR5]\]. However, the ratio of misdiagnosis in this study was 40.7%, higher than that previously reported. This was greatly influenced by the biopsy method. The meta-analysis found that one of the risk factors for underestimation of invasion was sampling by 14-Gauge CNB instead of 11-Gauge CNB. In contrast, for more than half of the cases in our study 16-Gauge CNB was used for biopsy. Therefore, in patients diagnosed with DCIS by VAB, the rate of postoperative invasion detection was 27.1%, in contrast with that found in patients diagnosed by CNB, which was 52.2%. Certainly, the use of VAB causes stronger pain and has higher medical costs than CNB. However, in the future, CNB with a thicker puncture needle or VAB is considered necessary for a more accurate preoperative diagnosis.

In addition to the different rate of postoperative invasion detected in our study, clinicopathological features also differed from those shown in the meta-analysis \[[@CR5]\]. According to the meta-analysis, only 8.3% of all cases diagnosed with DCIS by preoperative biopsy were palpable, and 98.3% were detected by breast cancer screening. While, the pathological diagnosis of high grade was 49.4%, accounting for about half of the cases, in this study, 64.4% of patients had symptoms and 72.0% were palpable. The pathological diagnosis of high grade was 16.9%, which was low. This may be due to the low screening rate in Japan. It is reported that the screening rate in Japan is about 40%, lower than in other countries \[[@CR19]\]. The number of DCIS detected early that could not be palpated was small; however, as they progressed, the proportion of patients with symptoms increased, and they became palpable. High grade DCIS may have been diagnosed as invasive ductal carcinoma at biopsy because it has already acquired invasiveness. The reason for a low ratio of a score of 3+ for HER2 may be the same. Although the rate of HER2 overexpression in DCIS has been reported to be from 28 to 65% \[[@CR20]\], the rate shown in this study was still lower. We considered that the low ratio of high grade DCIS caused this discrepancy because high grade DCIS was reported to be frequently negative for ER and overexpress HER2 \[[@CR20]\].

Various factors other than biopsy devices are considered risk factors for underestimation of invasion; high grade, tumor size larger than 20 mm, and palpability have been previously identified as risk factors \[[@CR5]\]. One study also reported hormone receptor negativity as a risk factor \[[@CR21]\]. There are reports suggesting that comedonecrosis, intraductal calcification, and lymphoid infiltrate are risk factors \[[@CR16], [@CR17]\]. Although this study showed differences in the ratio of invasion by postoperative pathology and clinicopathological features from those presented in previous reports, similar results were found regarding risk factors. However, this study focused on preoperative blood test results, and invasion in postoperative pathology was found significantly more frequently in patients with a high PLR than in patients with a low PLR. Platelets and growth factors such as platelet-derived growth factor and transforming growth factor-β are known to promote tumor growth \[[@CR22]--[@CR26]\]. In addition, immunity is involved in the progression of cancer, and lymphocytes play a key role in the host anti-tumor immune function \[[@CR27]\]. This study was based on the hypothesis that blood test changes may occur as cancer progresses. LDH and tumor markers showed no significant difference based on pre- and postoperative concordance, but invasion was significantly more likely to be found in the high PLR group than in the low PLR group. Perhaps PLR did not rise because of the invasion, but in an environment with a high PLR, the tumor could easily acquire invasive ability. High proliferative potential and malignancy, such as HER2-positive and high nuclear grade, cause comedonecrosis and intraductal calcification. If invasion appears, the invasive cancer may have caused inflammation in the surrounding interstitium. In recent years, one study has reported changes in the immune microenvironment of tumors in DCIS and IDC. According to this report, immune escape is progressing in the invasion part \[[@CR28]\]. In other words, the trigger of invasion requires a deterioration of the immune environment, and PLR may be the indicator for such deterioration. Although the actions of platelets and lymphocytes are generally reported, it is uncertain whether they actually affect DCIS. In future, we need to examine the biological effects of platelets and lymphocytes on DCIS by immunostaining, gene analysis, and protein quantification in vitro.

There are some limitations to this study. First, there were many cases, in which biopsy was performed with 16-Gauge CNB, so the rate of IDC detection after the surgery was higher than that shown in previous reports. Secondly, some clinicopathological features, such as the ratio of palpability or the grade of DCIS, also differed from those shown in previous reports. The usefulness of mammography scores, so-called the Breast Imaging Reporting and Data System (BI-RADS), has also been reported as a predictor \[[@CR5]\]. Third, in this study only 65 patients (55.1%) had mammography performed. Finally, since liver diseases and inflammation easily affect the absolute platelet count and lymphocyte count, it is also a limitation that the comorbidities were not included in the study. However, randomized trials are currently underway to investigate the outcomes during follow-up for low-grade DCIS \[[@CR29], [@CR30]\]. One strength of this study is that the PLR can be evaluated relatively easily in clinical practice, and changes in DCIS can be found by evaluating the PLR over time. Furthermore, the current trend is that sentinel lymph node biopsy is being omitted in the diagnosis of DCIS \[[@CR31], [@CR32]\]. Some studies reported that metastasis to the sentinel lymph node is unlikely to be found by sentinel lymph node biopsy during surgery for DCIS \[[@CR31], [@CR33]\]. If the PLR is high, the invasion may be found by postoperative pathological examination. In addition, chemotherapy may be less effective among these patients. Therefore, we believe that sentinel lymph node biopsy may still be needed in patients with high PLR.

Conclusions {#Sec10}
===========

The PLR may be a predictor of invasion in postoperative pathology for patients diagnosed with DCIS by preoperative biopsy.
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